Oxford Biomedica

Oxford Biomedica, trading as OXB, is a contract development and manufacturing organisation (CDMO) working in cell and gene therapy. The company develops and manufactures viral vectors - lentiviral, AAV and adenoviral among them - and provides services spanning process development, GMP manufacturing, analytical methods development, quality assurance and quality services, regulatory support and technology transfer. Its offering runs from preclinical work through commercial launch.

For those working in regulatory, quality and compliance functions, the operating context is a heavily governed one. Work is conducted under GMP conditions across biomanufacturing, analytics and technology transfer, with quality services and regulatory support forming part of the company's core service line rather than an adjunct to it. OXB describes itself as quality and innovation-led, and emphasises technical rigour, continuous improvement and practical innovation.

The company operates five facilities across three countries: Oxfordshire in the United Kingdom; Lyon and Strasbourg in France; and Bedford, Massachusetts, and Durham, North Carolina, in the United States. Teams are multidisciplinary, bringing together scientists, engineers, manufacturing specialists and commercial staff around the delivery of cell and gene therapies to patients. An Innovation and Technology Excellence Board brings external scientific and biomanufacturing expertise to bear on technology priorities and industry trends. The organisation's stated values are responsible, responsive, resilient and respectful.